Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial

Urinary Incontinence

Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

J Urol

Takahashi S, Kato K, Yokoyama O, Takei M, Gotoh M

doi: 10.1097/JU.0000000000004024

Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial

J Urol

Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S

doi: 10.1097/JU.0000000000003999

Urinary Incontinence

Double-blinded randomized controlled trial of Erbium-YAG Laser to treat Female Stress Urinary Incontinence

Am J Obstet Gynecol

Lee P, Perruzza D, Edell H, Jarvi S, Kim K, Sultana R, Alavi N, Kiss A, Cao X, Gagnon LH, Bodley J, Carr L, Herschorn S, Kung R

doi: 10.1016/j.ajog.2024.11.021

Urinary Incontinence

Two-year efficacy and safety outcomes of the pivotal OASIS Study using the Revi(®) System for treatment of urgency urinary incontinence

J Urol

Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, Digesu A, Amundsen CL, McCrery RJ, De Wachter S, Kean ER, Martens F, Benson K, Ferrante KL, Cline KJ, Padron OF, Giusto L, Lane FL, Witte LPW, Dmochowski RR

doi: 10.1097/JU.0000000000004328

Endometriosis

Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: 12 months of an ongoing randomized phase 3 trial

Am J Obstet Gynecol

Miller CE, Kim JH, Kroll R, Simon JA, Soliman AM, Thomas JW, Xu Y, Ng J, Snabes MC

doi: 10.1016/j.ajog.2024.06.040

Further Publications Gynecology

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder

J Sex Med

Thurman AR, Johnson I, Cornell KA, Hatheway J, Kim NN, Parish SJ, Dart C, Friend DR, Goldstein A

doi: 10.1093/jsxmed/qdae089

Uro-Oncology

Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial

J Urol

Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN

doi: 10.1097/JU.0000000000004020

Erectile and Sexual Functions and Dysfunctions

Comparison of the effectiveness of 2 shockwave therapy protocols for the treatment of vascular erectile dysfunction: a randomized, multicenter, open-label, noninferiority, phase 4 clinical trial

J Sex Med

Corredor HA, Sandoval-Salinas C, Martinez JM, Barba J, Patrón F

doi: 10.1093/jsxmed/qdae205

Endometriosis

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)

Hum Reprod

Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A, Paszkowski M, Petraglia F, Renner SP, Patel A, Boolell M, Bestel E, Dolmans MM

doi: 10.1093/humrep/deae076

Related content

Efficacy and Safety of TAS-303 in Female Patients With Stress Urinary Incontinence: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial

Double-blinded randomized controlled trial of Erbium-YAG Laser to treat Female Stress Urinary Incontinence

Two-year efficacy and safety outcomes of the pivotal OASIS Study using the Revi(®) System for treatment of urgency urinary incontinence

Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: 12 months of an ongoing randomized phase 3 trial

Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorder

Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial

Comparison of the effectiveness of 2 shockwave therapy protocols for the treatment of vascular erectile dysfunction: a randomized, multicenter, open-label, noninferiority, phase 4 clinical trial

Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3)